# Medical Equipment — company-by-company sector analysis

> Medical Equipment: Poly Medicure Ltd owns the largest revenue base; Prevest Denpro Ltd has the fastest current growth.

Sector Alpha — machine-written from the numbers. Data as of 2026-08-05. Not investment advice.

## Bottom line

Medical Equipment has underperformed NIFTY 500 by 19% over 52 weeks and 15.4% over 13 weeks. 3 of 6 covered companies beat NIFTY on Mansfield relative strength, while 2 of 5 beat the sector itself. Poly Medicure Ltd leads with revenue of ₹1,876 crore, based on 5 of 6 comparable companies through Mar 2026.

## Sector relative strength

Medical Equipment has underperformed NIFTY 500 by 19% over the last 52 weeks. Over 13 weeks the gap is a lead of 15.4%. 3 of 6 covered companies currently beat NIFTY on Mansfield relative strength, so leadership inside the sector is selective. Prevest Denpro Ltd is the strongest against the sector itself at +21.2%. Readings are as of 2026-07-19.

13-week sector return versus NIFTY 500: 15%
52-week sector return versus NIFTY 500: -19%
Stocks leading NIFTY: 3/6
Stocks leading sector: 2/5

Central tension: The central tension: the companies with the most scale are not necessarily the companies creating the most change.

Companies: 6
Combined market value: ₹21.8K Cr

## 4-Factor Sector Score

An additive sector-relative research score. The four displayed point contributions always equal the total: Growth & earnings (35), Capital efficiency (25), Valuation (20), and Relative strength (20). Missing or stale evidence is absorbed inside the affected factor, never applied as a hidden adjustment.

1. Prevest Denpro Ltd (PREVEST): 71/100 — Favorable setup; evidence 72%
   - Growth & earnings 23.4/35 | Capital efficiency 20.8/25 | Valuation 13.8/20 | Relative strength 13.3/20
   - Led NIFTY 500 by 5%+ over the prior 13 weeks in 3 of the last 12 weeks, ending 2026-03-08 (no longer priced)
   - Exact sum: 23.4 + 20.8 + 13.8 + 13.3 = 71.3
   - Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence.
2. Laxmi Dental Ltd (LAXMIDENTL): 49/100 — Mixed-negative evidence; evidence 74%
   - Growth & earnings 23.1/35 | Capital efficiency 11.8/25 | Valuation 10.3/20 | Relative strength 3.6/20
   - Price stage: TURNING — Ahead of the benchmark for one to four weeks, after a stretch of being behind.
   - Led NIFTY 500 by 5%+ over the prior 13 weeks in 11 of 11 weeks with a reading, within the last 12
   - Exact sum: 23.1 + 11.8 + 10.3 + 3.6 = 48.8
   - Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -18.5% and the one-year return is -53.6%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth.
3. Poly Medicure Ltd (POLYMED): 41/100 — Mixed-negative evidence; evidence 94%
   - Growth & earnings 12.6/35 | Capital efficiency 11.6/25 | Valuation 4.3/20 | Relative strength 12.4/20
   - Price stage: TURNING — Ahead of the benchmark for one to four weeks, after a stretch of being behind.
   - Led NIFTY 500 by 5%+ over the prior 13 weeks in 9 of 10 weeks with a reading, within the last 12
   - Exact sum: 12.6 + 11.6 + 4.3 + 12.4 = 40.9
   - Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
4. Tarsons Products Ltd (TARSONS): 34/100 — Adverse evidence; evidence 81%
   - Growth & earnings 8.4/35 | Capital efficiency 8.4/25 | Valuation 5.4/20 | Relative strength 11.3/20
   - Price stage: TURNING — Ahead of the benchmark for one to four weeks, after a stretch of being behind.
   - Led NIFTY 500 by 5%+ over the prior 13 weeks in 9 of 10 weeks with a reading, within the last 12
   - Exact sum: 8.4 + 8.4 + 5.4 + 11.3 = 33.5
   - Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
5. Vasa Denticity Ltd (DENTALKART): 23/100 — Adverse evidence; evidence 81%
   - Growth & earnings 6.7/35 | Capital efficiency 4.8/25 | Valuation 7.0/20 | Relative strength 4.5/20
   - Price stage: ASLEEP — Neither ahead of the benchmark nor yet turning up against it.
   - Led NIFTY 500 by 5%+ over the prior 13 weeks in 2 of 10 weeks with a reading, within the last 12
   - Exact sum: 6.7 + 4.8 + 7 + 4.5 = 23
   - Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
6. Hemant Surgical Industries Ltd (543916): 57/100 — Thin evidence · provisional; evidence 31%
   - Growth & earnings 18.1/35 | Capital efficiency 15.7/25 | Valuation 10.9/20 | Relative strength 11.9/20
   - Price stage: BREAKING OUT — Ahead of the benchmark five weeks or more running, with its lead holding or widening.
   - Led NIFTY 500 by 5%+ over the prior 13 weeks in 6 of 6 weeks with a reading, within the last 12
   - Exact sum: 18.1 + 15.7 + 10.9 + 11.9 = 56.6
   - Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

## Market action

Tarsons Products Ltd has the strongest one-year price move in Medical Equipment at -15.9%. It also leads on Mansfield relative strength against NIFTY at +25.5%. 3 of 6 covered companies are above zero on that measure. Every line covers 313 weekly closes through 2026-07-31.

### Strongest one-year price performers
1. Tarsons Products Ltd (TARSONS): -16%
2. Poly Medicure Ltd (POLYMED): -17%
3. Prevest Denpro Ltd (PREVEST): -23%
4. Vasa Denticity Ltd (DENTALKART): -35%
5. Laxmi Dental Ltd (LAXMIDENTL): -54%

### Strongest relative strength versus NIFTY 500
1. Tarsons Products Ltd (TARSONS): 26%
2. Hemant Surgical Industries Ltd (543916): 19%
3. Poly Medicure Ltd (POLYMED): 0.2%
4. Prevest Denpro Ltd (PREVEST): -13%
5. Laxmi Dental Ltd (LAXMIDENTL): -16%

## Revenue Scale & Growth Durability

What the numbers say: Poly Medicure Ltd is the scale leader at ₹1,876 crore, 344% ahead of Tarsons Products Ltd. Prevest Denpro Ltd's growth is 17.3% from a ₹71 crore base, with 13 reported observations in the 20-quarter window. Treat the growth leader as an acceleration candidate, not as equally proven scale.

Investor read: Poly Medicure Ltd is the scale benchmark; Prevest Denpro Ltd is the acceleration watch. Promote the challenger only if growth persists and converts into margin and returns.

This conclusion weakens if: Poly Medicure Ltd's growth falls below Prevest Denpro Ltd's for two consecutive comparable reports while operating margin also compresses.

Evidence: Poly Medicure Ltd · ₹1,876 crore | 344% versus #2 · Tarsons Products Ltd | 8/8 recent comparable periods | 5/6 companies · 71 observations

Definition: Revenue is compared on a common reported-currency basis. Growth is year-on-year, so seasonality does not masquerade as progress.

### Revenue — largest
1. Poly Medicure Ltd (POLYMED): ₹1.9K Cr
2. Tarsons Products Ltd (TARSONS): ₹423 Cr
3. Vasa Denticity Ltd (DENTALKART): ₹279 Cr
4. Laxmi Dental Ltd (LAXMIDENTL): ₹278 Cr
5. Prevest Denpro Ltd (PREVEST): ₹71 Cr

### Revenue growth — fastest growers
1. Prevest Denpro Ltd (PREVEST): 17%
2. Laxmi Dental Ltd (LAXMIDENTL): 16%
3. Poly Medicure Ltd (POLYMED): 12%
4. Vasa Denticity Ltd (DENTALKART): 12%
5. Tarsons Products Ltd (TARSONS): 7.7%

### 20-quarter Revenue history
- 543916: Jun 2021 — | Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 — | Dec 2024 — | Mar 2025 ₹58 Cr | Jun 2025 — | Sep 2025 ₹65 Cr | Dec 2025 — | Mar 2026 ₹167 Cr
- POLYMED: Jun 2021 ₹212 Cr | Sep 2021 ₹223 Cr | Dec 2021 ₹230 Cr | Mar 2022 ₹257 Cr | Jun 2022 ₹249 Cr | Sep 2022 ₹275 Cr | Dec 2022 ₹285 Cr | Mar 2023 ₹307 Cr | Jun 2023 ₹321 Cr | Sep 2023 ₹337 Cr | Dec 2023 ₹340 Cr | Mar 2024 ₹378 Cr | Jun 2024 ₹385 Cr | Sep 2024 ₹420 Cr | Dec 2024 ₹424 Cr | Mar 2025 ₹441 Cr | Jun 2025 ₹403 Cr | Sep 2025 ₹444 Cr | Dec 2025 ₹494 Cr | Mar 2026 ₹535 Cr
- TARSONS: Jun 2021 ₹69 Cr | Sep 2021 ₹76 Cr | Dec 2021 ₹71 Cr | Mar 2022 ₹85 Cr | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 ₹62 Cr | Mar 2024 ₹106 Cr | Jun 2024 ₹85 Cr | Sep 2024 ₹99 Cr | Dec 2024 ₹96 Cr | Mar 2025 ₹113 Cr | Jun 2025 ₹91 Cr | Sep 2025 ₹102 Cr | Dec 2025 ₹108 Cr | Mar 2026 ₹121 Cr
- LAXMIDENTL: Jun 2021 — | Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 ₹48 Cr | Mar 2024 ₹55 Cr | Jun 2024 ₹60 Cr | Sep 2024 ₹57 Cr | Dec 2024 ₹62 Cr | Mar 2025 ₹61 Cr | Jun 2025 ₹66 Cr | Sep 2025 ₹72 Cr | Dec 2025 ₹66 Cr | Mar 2026 ₹74 Cr
- DENTALKART: Jun 2021 — | Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 ₹41 Cr | Dec 2023 ₹37 Cr | Mar 2024 ₹57 Cr | Jun 2024 ₹54 Cr | Sep 2024 ₹59 Cr | Dec 2024 ₹63 Cr | Mar 2025 ₹73 Cr | Jun 2025 ₹61 Cr | Sep 2025 ₹73 Cr | Dec 2025 ₹72 Cr | Mar 2026 ₹73 Cr
- PREVEST: Jun 2021 — | Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 ₹12 Cr | Mar 2023 ₹14 Cr | Jun 2023 ₹13 Cr | Sep 2023 ₹13 Cr | Dec 2023 ₹14 Cr | Mar 2024 ₹16 Cr | Jun 2024 ₹13 Cr | Sep 2024 ₹16 Cr | Dec 2024 ₹15 Cr | Mar 2025 ₹19 Cr | Jun 2025 ₹16 Cr | Sep 2025 ₹19 Cr | Dec 2025 ₹18 Cr | Mar 2026 —

### 20-quarter Revenue growth history
- 543916: Jun 2021 — | Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 — | Dec 2024 — | Mar 2025 — | Jun 2025 — | Sep 2025 — | Dec 2025 — | Mar 2026 188%
- POLYMED: Jun 2021 — | Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 17% | Sep 2022 23% | Dec 2022 24% | Mar 2023 19% | Jun 2023 29% | Sep 2023 23% | Dec 2023 19% | Mar 2024 23% | Jun 2024 20% | Sep 2024 25% | Dec 2024 25% | Mar 2025 17% | Jun 2025 4.7% | Sep 2025 5.7% | Dec 2025 17% | Mar 2026 21%
- TARSONS: Jun 2021 — | Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 — | Dec 2024 55% | Mar 2025 6.6% | Jun 2025 7.7% | Sep 2025 3.1% | Dec 2025 13% | Mar 2026 7.3%
- LAXMIDENTL: Jun 2021 — | Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 — | Dec 2024 29% | Mar 2025 11% | Jun 2025 10% | Sep 2025 26% | Dec 2025 6.5% | Mar 2026 21%
- DENTALKART: Jun 2021 — | Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 46% | Dec 2024 71% | Mar 2025 28% | Jun 2025 13% | Sep 2025 23% | Dec 2025 15% | Mar 2026 0.3%
- PREVEST: Jun 2021 — | Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 11% | Mar 2024 18% | Jun 2024 -0.4% | Sep 2024 23% | Dec 2024 9.6% | Mar 2025 14% | Jun 2025 18% | Sep 2025 15% | Dec 2025 23% | Mar 2026 —

## Operating Economics & Margin Trend

What the numbers say: Prevest Denpro Ltd leads opm at 33.9%; Laxmi Dental Ltd leads margin change at +2 percentage points.

Investor read: Prevest Denpro Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.

This conclusion weakens if: The next two comparable reports reverse the current margin change signal.

Evidence: Prevest Denpro Ltd · 33.9% | 19.8% versus #2 · Tarsons Products Ltd | 4/8 recent comparable periods | 6/6 companies · 84 observations

Definition: Operating margin compares operating profit with revenue. Improvement is measured in percentage points, not percentage growth.

### OPM — highest
1. Prevest Denpro Ltd (PREVEST): 34%
2. Tarsons Products Ltd (TARSONS): 28%
3. Poly Medicure Ltd (POLYMED): 21%
4. Laxmi Dental Ltd (LAXMIDENTL): 18%
5. Hemant Surgical Industries Ltd (543916): 9.0%

### Margin change — fastest expanders
1. Laxmi Dental Ltd (LAXMIDENTL): +2.0 pp
2. Hemant Surgical Industries Ltd (543916): 0.0 pp
3. Prevest Denpro Ltd (PREVEST): −0.6 pp
4. Tarsons Products Ltd (TARSONS): −4.5 pp
5. Poly Medicure Ltd (POLYMED): −6.0 pp

### 20-quarter OPM history
- 543916: Jun 2021 — | Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 8.0% | Dec 2022 — | Mar 2023 11% | Jun 2023 — | Sep 2023 6.6% | Dec 2023 — | Mar 2024 13% | Jun 2024 — | Sep 2024 7.2% | Dec 2024 — | Mar 2025 9.0% | Jun 2025 — | Sep 2025 12% | Dec 2025 — | Mar 2026 9.0%
- POLYMED: Jun 2021 26% | Sep 2021 23% | Dec 2021 22% | Mar 2022 22% | Jun 2022 19% | Sep 2022 24% | Dec 2022 25% | Mar 2023 27% | Jun 2023 27% | Sep 2023 25% | Dec 2023 27% | Mar 2024 26% | Jun 2024 27% | Sep 2024 27% | Dec 2024 27% | Mar 2025 27% | Jun 2025 26% | Sep 2025 26% | Dec 2025 23% | Mar 2026 21%
- TARSONS: Jun 2021 53% | Sep 2021 51% | Dec 2021 47% | Mar 2022 52% | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 37% | Mar 2024 29% | Jun 2024 22% | Sep 2024 26% | Dec 2024 31% | Mar 2025 33% | Jun 2025 27% | Sep 2025 27% | Dec 2025 29% | Mar 2026 28%
- LAXMIDENTL: Jun 2021 — | Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 8.0% | Mar 2024 21% | Jun 2024 23% | Sep 2024 15% | Dec 2024 16% | Mar 2025 16% | Jun 2025 18% | Sep 2025 15% | Dec 2025 11% | Mar 2026 18%
- DENTALKART: Jun 2021 — | Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 7.5% | Dec 2022 — | Mar 2023 9.2% | Jun 2023 9.2% | Sep 2023 8.8% | Dec 2023 9.4% | Mar 2024 14% | Jun 2024 8.6% | Sep 2024 11% | Dec 2024 8.8% | Mar 2025 8.8% | Jun 2025 5.0% | Sep 2025 8.0% | Dec 2025 2.4% | Mar 2026 0.4%
- PREVEST: Jun 2021 — | Sep 2021 41% | Dec 2021 43% | Mar 2022 31% | Jun 2022 37% | Sep 2022 39% | Dec 2022 41% | Mar 2023 41% | Jun 2023 37% | Sep 2023 34% | Dec 2023 33% | Mar 2024 36% | Jun 2024 34% | Sep 2024 36% | Dec 2024 34% | Mar 2025 36% | Jun 2025 35% | Sep 2025 36% | Dec 2025 34% | Mar 2026 —

### 20-quarter Margin change history
- 543916: Jun 2021 — | Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 −1.5 pp | Dec 2023 — | Mar 2024 +1.7 pp | Jun 2024 — | Sep 2024 +0.7 pp | Dec 2024 — | Mar 2025 −3.7 pp | Jun 2025 — | Sep 2025 +4.8 pp | Dec 2025 — | Mar 2026 0.0 pp
- POLYMED: Jun 2021 −0.8 pp | Sep 2021 −5.5 pp | Dec 2021 −6.2 pp | Mar 2022 −3.8 pp | Jun 2022 −7.4 pp | Sep 2022 +0.8 pp | Dec 2022 +2.8 pp | Mar 2023 +5.4 pp | Jun 2023 +8.3 pp | Sep 2023 +1.5 pp | Dec 2023 +2.0 pp | Mar 2024 −1.0 pp | Jun 2024 0.0 pp | Sep 2024 +2.0 pp | Dec 2024 0.0 pp | Mar 2025 +1.0 pp | Jun 2025 −1.0 pp | Sep 2025 −1.0 pp | Dec 2025 −4.0 pp | Mar 2026 −6.0 pp
- TARSONS: Jun 2021 +25.7 pp | Sep 2021 — | Dec 2021 −4.0 pp | Mar 2022 +0.6 pp | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 — | Dec 2024 −6.1 pp | Mar 2025 +4.3 pp | Jun 2025 +4.9 pp | Sep 2025 +1.3 pp | Dec 2025 −1.8 pp | Mar 2026 −4.5 pp
- LAXMIDENTL: Jun 2021 — | Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 — | Dec 2024 +8.0 pp | Mar 2025 −5.0 pp | Jun 2025 −5.0 pp | Sep 2025 0.0 pp | Dec 2025 −5.0 pp | Mar 2026 +2.0 pp
- DENTALKART: Jun 2021 — | Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 +1.2 pp | Dec 2023 — | Mar 2024 +5.1 pp | Jun 2024 −0.6 pp | Sep 2024 +2.0 pp | Dec 2024 −0.6 pp | Mar 2025 −5.5 pp | Jun 2025 −3.6 pp | Sep 2025 −2.8 pp | Dec 2025 −6.4 pp | Mar 2026 −8.4 pp
- PREVEST: Jun 2021 — | Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 −2.3 pp | Dec 2022 −2.4 pp | Mar 2023 +9.6 pp | Jun 2023 +0.1 pp | Sep 2023 −4.7 pp | Dec 2023 −7.7 pp | Mar 2024 −4.5 pp | Jun 2024 −3.4 pp | Sep 2024 +1.6 pp | Dec 2024 +1.6 pp | Mar 2025 −0.5 pp | Jun 2025 +1.5 pp | Sep 2025 +0.2 pp | Dec 2025 −0.6 pp | Mar 2026 —

## Profit Scale & Acceleration

What the numbers say: Poly Medicure Ltd leads with ₹321 crore of TTM profit, 11.1× the profit of Laxmi Dental Ltd. Prevest Denpro Ltd shows 17% growth from a ₹21 crore profit base. Compare the size of the base and persistence before ranking acceleration above profit scale.

Investor read: Poly Medicure Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.

This conclusion weakens if: The next two comparable reports reverse the current profit growth signal.

Evidence: Poly Medicure Ltd · ₹321 crore | 11.1× versus #2 · Laxmi Dental Ltd | 6/8 recent comparable periods | 5/6 companies · 71 observations

Definition: Net profit is the residual after operating costs, interest and tax. Growth off a loss or near-zero base is excluded from the fastest-grower rank.

### Net profit — largest
1. Poly Medicure Ltd (POLYMED): ₹321 Cr
2. Laxmi Dental Ltd (LAXMIDENTL): ₹29 Cr
3. Prevest Denpro Ltd (PREVEST): ₹21 Cr
4. Tarsons Products Ltd (TARSONS): ₹14 Cr
5. Vasa Denticity Ltd (DENTALKART): ₹10 Cr

### Profit growth — fastest growers
1. Prevest Denpro Ltd (PREVEST): 17%
2. Poly Medicure Ltd (POLYMED): -5.0%
3. Laxmi Dental Ltd (LAXMIDENTL): -9.4%
4. Vasa Denticity Ltd (DENTALKART): -41%
5. Tarsons Products Ltd (TARSONS): -52%

### 20-quarter Net profit history
- 543916: Jun 2021 — | Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 — | Dec 2024 — | Mar 2025 ₹5 Cr | Jun 2025 — | Sep 2025 ₹5 Cr | Dec 2025 — | Mar 2026 ₹13 Cr
- POLYMED: Jun 2021 ₹38 Cr | Sep 2021 ₹38 Cr | Dec 2021 ₹35 Cr | Mar 2022 ₹36 Cr | Jun 2022 ₹27 Cr | Sep 2022 ₹43 Cr | Dec 2022 ₹50 Cr | Mar 2023 ₹59 Cr | Jun 2023 ₹63 Cr | Sep 2023 ₹62 Cr | Dec 2023 ₹65 Cr | Mar 2024 ₹68 Cr | Jun 2024 ₹74 Cr | Sep 2024 ₹87 Cr | Dec 2024 ₹85 Cr | Mar 2025 ₹92 Cr | Jun 2025 ₹93 Cr | Sep 2025 ₹92 Cr | Dec 2025 ₹71 Cr | Mar 2026 ₹65 Cr
- TARSONS: Jun 2021 ₹25 Cr | Sep 2021 ₹25 Cr | Dec 2021 ₹21 Cr | Mar 2022 ₹29 Cr | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 ₹10 Cr | Mar 2024 ₹10 Cr | Jun 2024 ₹4 Cr | Sep 2024 ₹10 Cr | Dec 2024 ₹5 Cr | Mar 2025 ₹10 Cr | Jun 2025 ₹2 Cr | Sep 2025 ₹3 Cr | Dec 2025 ₹5 Cr | Mar 2026 ₹4 Cr
- LAXMIDENTL: Jun 2021 — | Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 ₹2 Cr | Mar 2024 ₹8 Cr | Jun 2024 ₹17 Cr | Sep 2024 ₹6 Cr | Dec 2024 ₹5 Cr | Mar 2025 ₹4 Cr | Jun 2025 ₹8 Cr | Sep 2025 ₹9 Cr | Dec 2025 ₹2 Cr | Mar 2026 ₹10 Cr
- DENTALKART: Jun 2021 — | Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 ₹4 Cr | Dec 2023 ₹2 Cr | Mar 2024 ₹6 Cr | Jun 2024 ₹3 Cr | Sep 2024 ₹5 Cr | Dec 2024 ₹4 Cr | Mar 2025 ₹4 Cr | Jun 2025 ₹3 Cr | Sep 2025 ₹5 Cr | Dec 2025 ₹1 Cr | Mar 2026 ₹1 Cr
- PREVEST: Jun 2021 — | Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 ₹4 Cr | Mar 2023 ₹5 Cr | Jun 2023 ₹4 Cr | Sep 2023 ₹4 Cr | Dec 2023 ₹4 Cr | Mar 2024 ₹5 Cr | Jun 2024 ₹4 Cr | Sep 2024 ₹5 Cr | Dec 2024 ₹4 Cr | Mar 2025 ₹5 Cr | Jun 2025 ₹5 Cr | Sep 2025 ₹6 Cr | Dec 2025 ₹5 Cr | Mar 2026 —

### 20-quarter Profit growth history
- 543916: Jun 2021 — | Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 — | Dec 2024 — | Mar 2025 — | Jun 2025 — | Sep 2025 — | Dec 2025 — | Mar 2026 160%
- POLYMED: Jun 2021 — | Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 -29% | Sep 2022 13% | Dec 2022 43% | Mar 2023 64% | Jun 2023 133% | Sep 2023 44% | Dec 2023 30% | Mar 2024 15% | Jun 2024 17% | Sep 2024 40% | Dec 2024 31% | Mar 2025 35% | Jun 2025 26% | Sep 2025 5.8% | Dec 2025 -16% | Mar 2026 -29%
- TARSONS: Jun 2021 — | Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 — | Dec 2024 -47% | Mar 2025 -1.2% | Jun 2025 -56% | Sep 2025 -68% | Dec 2025 -4.2% | Mar 2026 -59%
- LAXMIDENTL: Jun 2021 — | Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 — | Dec 2024 150% | Mar 2025 -50% | Jun 2025 -53% | Sep 2025 50% | Dec 2025 -60% | Mar 2026 150%
- DENTALKART: Jun 2021 — | Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 44% | Dec 2024 63% | Mar 2025 -35% | Jun 2025 -21% | Sep 2025 -14% | Dec 2025 -66% | Mar 2026 -70%
- PREVEST: Jun 2021 — | Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 1.4% | Mar 2024 -8.8% | Jun 2024 -11% | Sep 2024 29% | Dec 2024 23% | Mar 2025 13% | Jun 2025 27% | Sep 2025 15% | Dec 2025 15% | Mar 2026 —

## Return On Capital Employed

What the numbers say: Prevest Denpro Ltd leads ROCE at 25.2%, 5.6 percentage points above Hemant Surgical Industries Ltd. Laxmi Dental Ltd has the strongest latest improvement at -1.4 percentage points. Read the leader beside the density of its reported history: a sparse high return is a candidate; a repeated high return is evidence of durability.

Investor read: Prevest Denpro Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.

This conclusion weakens if: The next two comparable reports reverse the current roce change signal.

Evidence: Prevest Denpro Ltd · 25.2% | 28.6% versus #2 · Hemant Surgical Industries Ltd | Not enough history | 6/6 companies · 47 observations

Definition: ROCE asks how much operating return the business earns on the capital employed. Direction matters, but a single exceptional year should not be mistaken for durability.

### ROCE — highest
1. Prevest Denpro Ltd (PREVEST): 25%
2. Hemant Surgical Industries Ltd (543916): 20%
3. Laxmi Dental Ltd (LAXMIDENTL): 15%
4. Poly Medicure Ltd (POLYMED): 14%
5. Vasa Denticity Ltd (DENTALKART): 8.6%

### ROCE change — fastest improvers
1. Laxmi Dental Ltd (LAXMIDENTL): −1.4 pp
2. Prevest Denpro Ltd (PREVEST): −2.0 pp
3. Tarsons Products Ltd (TARSONS): −2.6 pp
4. Poly Medicure Ltd (POLYMED): −3.4 pp
5. Vasa Denticity Ltd (DENTALKART): −10.8 pp

### 20-quarter ROCE history
- POLYMED: Jun 2021 — | Sep 2021 15% | Dec 2021 — | Mar 2022 14% | Jun 2022 — | Sep 2022 14% | Dec 2022 — | Mar 2023 17% | Jun 2023 — | Sep 2023 20% | Dec 2023 26% | Mar 2024 20% | Jun 2024 27% | Sep 2024 13% | Dec 2024 22% | Mar 2025 13% | Jun 2025 23% | Sep 2025 12% | Dec 2025 17% | Mar 2026 9.8%
- TARSONS: Jun 2021 36% | Sep 2021 — | Dec 2021 — | Mar 2022 26% | Jun 2022 — | Sep 2022 21% | Dec 2022 — | Mar 2023 15% | Jun 2023 — | Sep 2023 12% | Dec 2023 — | Mar 2024 6.5% | Jun 2024 — | Sep 2024 4.8% | Dec 2024 8.5% | Mar 2025 4.9% | Jun 2025 7.4% | Sep 2025 3.8% | Dec 2025 6.1% | Mar 2026 2.3%
- LAXMIDENTL: Jun 2021 — | Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 15% | Jun 2024 — | Sep 2024 27% | Dec 2024 40% | Mar 2025 12% | Jun 2025 20% | Sep 2025 11% | Dec 2025 15% | Mar 2026 11%
- DENTALKART: Jun 2021 — | Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 16% | Jun 2023 — | Sep 2023 15% | Dec 2023 — | Mar 2024 25% | Jun 2024 48% | Sep 2024 27% | Dec 2024 37% | Mar 2025 16% | Jun 2025 22% | Sep 2025 11% | Dec 2025 14% | Mar 2026 5.0%

### 20-quarter ROCE change history
- POLYMED: Jun 2021 — | Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 −1.4 pp | Dec 2022 — | Mar 2023 +2.7 pp | Jun 2023 — | Sep 2023 +5.8 pp | Dec 2023 — | Mar 2024 +3.1 pp | Jun 2024 — | Sep 2024 −6.9 pp | Dec 2024 −4.7 pp | Mar 2025 −6.5 pp | Jun 2025 −4.0 pp | Sep 2025 −0.9 pp | Dec 2025 −4.8 pp | Mar 2026 −3.4 pp
- TARSONS: Jun 2021 — | Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 −10.4 pp | Jun 2023 — | Sep 2023 −9.3 pp | Dec 2023 — | Mar 2024 −8.8 pp | Jun 2024 — | Sep 2024 −6.8 pp | Dec 2024 — | Mar 2025 −1.6 pp | Jun 2025 — | Sep 2025 −1.0 pp | Dec 2025 −2.4 pp | Mar 2026 −2.6 pp
- LAXMIDENTL: Jun 2021 — | Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 — | Dec 2024 — | Mar 2025 −3.2 pp | Jun 2025 — | Sep 2025 −16.2 pp | Dec 2025 −25.0 pp | Mar 2026 −1.4 pp
- DENTALKART: Jun 2021 — | Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 +8.8 pp | Jun 2024 — | Sep 2024 +12.3 pp | Dec 2024 — | Mar 2025 −9.4 pp | Jun 2025 −26.1 pp | Sep 2025 −16.4 pp | Dec 2025 −22.5 pp | Mar 2026 −10.8 pp

## Valuation Against Growth & Quality

What the numbers say: Poly Medicure Ltd has the lowest comparable PEG at 3.87×. Only 1 of 6 companies have earnings and growth steady enough for the ratio to mean anything, so no broad “cheapest stock” conclusion is defensible unless the current multiple, own-history position and growth durability agree.

Investor read: Treat valuation as permission to investigate, never as a standalone reason to buy.

This conclusion weakens if: The next two comparable reports reverse the current p/e signal.

Evidence: Poly Medicure Ltd · 3.87× | Not enough peers | 0/8 recent comparable periods | 1/6 companies · 16 observations

Definition: PEG is shown only when earnings are positive and three-year EPS growth is between 5% and 60%. It is recomputed consistently as the trailing P/E divided by that growth rate — reported earnings, never an expected-earnings multiple. On Indian companies it is shown only where the two data feeds agreed. Where any of that fails the ratio is left out rather than printed: a P/E divided by a loss, or by growth measured off a tiny base, is a number that looks precise and means nothing.

### PEG — lowest PEG
1. Poly Medicure Ltd (POLYMED): 3.9

### P/E — lowest P/E
1. Prevest Denpro Ltd (PREVEST): 24.8
2. Hemant Surgical Industries Ltd (543916): 30.1
3. Laxmi Dental Ltd (LAXMIDENTL): 35.0
4. Poly Medicure Ltd (POLYMED): 52.7
5. Vasa Denticity Ltd (DENTALKART): 66.7

### 20-quarter PEG history
- POLYMED: Jun 2021 2.2 | Sep 2021 1.6 | Dec 2021 2.1 | Mar 2022 3.7 | Jun 2022 — | Sep 2022 — | Dec 2022 1.4 | Mar 2023 — | Jun 2023 2.8 | Sep 2023 1.1 | Dec 2023 2.0 | Mar 2024 1.0 | Jun 2024 1.6 | Sep 2024 3.2 | Dec 2024 3.5 | Mar 2025 3.1 | Jun 2025 2.5 | Sep 2025 — | Dec 2025 2.7 | Mar 2026 3.9

### 20-quarter P/E history
- 543916: Jun 2021 — | Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 — | Dec 2024 — | Mar 2025 — | Jun 2025 — | Sep 2025 42.9 | Dec 2025 — | Mar 2026 27.5
- POLYMED: Jun 2021 65.7 | Sep 2021 60.0 | Dec 2021 60.0 | Mar 2022 54.5 | Jun 2022 48.8 | Sep 2022 61.1 | Dec 2022 61.0 | Mar 2023 58.3 | Jun 2023 61.5 | Sep 2023 61.3 | Dec 2023 61.2 | Mar 2024 61.3 | Jun 2024 71.7 | Sep 2024 81.0 | Dec 2024 83.6 | Mar 2025 70.4 | Jun 2025 63.5 | Sep 2025 55.5 | Dec 2025 49.2 | Mar 2026 35.4
- TARSONS: Jun 2021 — | Sep 2021 — | Dec 2021 0.2 | Mar 2022 0.2 | Jun 2022 36.1 | Sep 2022 43.1 | Dec 2022 36.7 | Mar 2023 28.1 | Jun 2023 31.9 | Sep 2023 27.8 | Dec 2023 27.9 | Mar 2024 20.8 | Jun 2024 26.4 | Sep 2024 54.7 | Dec 2024 65.3 | Mar 2025 53.7 | Jun 2025 68.8 | Sep 2025 59.4 | Dec 2025 59.8 | Mar 2026 44.3
- LAXMIDENTL: Jun 2021 — | Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 — | Dec 2024 — | Mar 2025 1.6 | Jun 2025 54.6 | Sep 2025 60.1 | Dec 2025 57.5 | Mar 2026 33.1
- DENTALKART: Jun 2021 — | Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 91.8 | Sep 2023 76.9 | Dec 2023 87.7 | Mar 2024 52.1 | Jun 2024 63.5 | Sep 2024 68.7 | Dec 2024 66.8 | Mar 2025 52.7 | Jun 2025 61.5 | Sep 2025 62.0 | Dec 2025 60.3 | Mar 2026 45.5
- PREVEST: Jun 2021 — | Sep 2021 — | Dec 2021 1.7 | Mar 2022 1.5 | Jun 2022 28.2 | Sep 2022 40.7 | Dec 2022 32.7 | Mar 2023 25.6 | Jun 2023 39.2 | Sep 2023 33.9 | Dec 2023 30.4 | Mar 2024 25.6 | Jun 2024 37.1 | Sep 2024 45.9 | Dec 2024 44.4 | Mar 2025 31.9 | Jun 2025 35.4 | Sep 2025 36.3 | Dec 2025 28.8 | Mar 2026 —


## What can make this comparison misleading?
- A high growth rate can be a low-base artefact. The page keeps level and change separate for that reason.
- A high ROCE can be temporary or flattered by a small capital base. Read it beside margin, cash conversion and reinvestment.
- The 4-Factor Sector Score ranks research priority, not portfolio action. Management quality, catalysts and risks need equally fresh evidence before capital is deployed.
- An “all companies” line chart preserves completeness, but rank changes should be checked against reporting dates before drawing a conclusion.
- 3 companies draw at least one figure from a second data feed with too little overlapping history to cross-check against the primary source; they are marked unverified wherever those figures appear.
- Thin comparisons: Valuation have fewer than three usable current readings.

## Every company
- Poly Medicure Ltd (POLYMED) — market value ₹17.3K Cr; latest fundamentals Mar 2026
- Tarsons Products Ltd (TARSONS) — market value ₹1.7K Cr; latest fundamentals Mar 2026; includes UNVERIFIED second-feed figures
- Laxmi Dental Ltd (LAXMIDENTL) — market value ₹1.2K Cr; latest fundamentals Mar 2026; includes UNVERIFIED second-feed figures
- Vasa Denticity Ltd (DENTALKART) — market value ₹683 Cr; latest fundamentals Mar 2026; includes UNVERIFIED second-feed figures
- Hemant Surgical Industries Ltd (543916) — market value ₹547 Cr; latest fundamentals Mar 2026
- Prevest Denpro Ltd (PREVEST) — market value ₹510 Cr; latest fundamentals Dec 2025

## Source standing of each company

Cross-checked: 1. Unverified: 5. Withheld: 0. Graded companies: 6.

3 of 6 companies draw at least one figure from a second data feed that could not be cross-checked against the primary source, because the two do not share enough reported history to compare. Those figures are marked unverified wherever they appear.

- UNVERIFIED | TARSONS | Tarsons Products Ltd | too little overlapping reported history to cross-check the second feed
- UNVERIFIED | LAXMIDENTL | Laxmi Dental Ltd | too little overlapping reported history to cross-check the second feed
- UNVERIFIED | DENTALKART | Vasa Denticity Ltd | too little overlapping reported history to cross-check the second feed

## Methodology and freshness

Fundamentals through Mar 2026; prices through 2026-07-31.
Up to 20 quarters per company. Reported history is normalized to Indian rupees crore. Missing values are not interpolated. Derived metrics are calculated only when their inputs are comparable.

## Frequently asked questions

### Is the Medical Equipment sector outperforming NIFTY 500?

Medical Equipment has underperformed NIFTY 500 by 19% over 52 weeks and 15.4% over 13 weeks. 3 of 6 covered companies beat NIFTY on Mansfield relative strength, while 2 of 5 beat the sector itself.

### Which Medical Equipment company is largest by revenue?

Poly Medicure Ltd leads with revenue of ₹1,876 crore, based on 5 of 6 comparable companies through Mar 2026.

### Which Medical Equipment company is growing fastest?

Prevest Denpro Ltd has the fastest current revenue growth at 17.3%, across 5 of 6 comparable companies.

### Which Medical Equipment company has the strongest 4-Factor Sector Score?

Prevest Denpro Ltd ranks first at 71.3/100 with 72.1% evidence confidence. The score prioritizes research; it is not a buy recommendation.

### Which Medical Equipment company has the lowest comparable PEG?

Poly Medicure Ltd has the lowest comparable PEG at 3.87, among 1 of 6 companies whose earnings and growth are steady enough for the ratio to mean anything.

### How much history does this Medical Equipment comparison include?

The page compares up to 20 reported quarters per company for fundamentals, returns and valuation, ending Mar 2026. Missing observations remain blank rather than being estimated.

### How is the 4-Factor Sector Score calculated?

The four visible contributions add directly: growth and earnings up to 35 points, capital efficiency up to 25, valuation up to 20, and relative strength up to 20. Missing or stale evidence moves only the affected contribution toward neutral.

### What is the Nifty Medical Equipment index?

The Nifty Medical Equipment index tracks India's listed Medical Equipment companies as a single basket. This page follows the same 6 companies and equal-weights them, so every company's weekly return counts once whatever it is worth, and the reading belongs to the Medical Equipment sector rather than to its largest constituent. Figures are as of Mar 2026.

### Which are the best Medical Equipment stocks in India?

Ranked by this page's four-factor score, Prevest Denpro Ltd places first among 6 listed Medical Equipment companies, followed by Laxmi Dental Ltd. That is a ranking of published data — earnings, quality, valuation and market behaviour as of Mar 2026 — and not a recommendation; Sector Alpha is not registered with SEBI as an investment adviser.

### How many Medical Equipment stocks are listed in India?

This comparison covers 6 listed Medical Equipment companies in India, each above the size floor the site applies, with 20 quarters of reported figures per company where the filings exist. The full ranked list is on this page, as of Mar 2026.

### Which Medical Equipment company is the biggest?

Poly Medicure Ltd is the largest, with trailing-twelve-month revenue of ₹1,876 crore, ahead of Tarsons Products Ltd at ₹423 crore. That covers 5 of 6 companies with comparable reporting through Mar 2026.

### Which Medical Equipment company has the best profit margins?

Prevest Denpro Ltd has the highest operating margin at 33.9%, from 6 of 6 comparable companies. Laxmi Dental Ltd shows the biggest recent improvement, at +2 percentage points. A high margin matters most when it is holding or rising, not when it is peaking.

### Which Medical Equipment company makes the most profit?

Poly Medicure Ltd earns the most, at ₹321 crore of trailing-twelve-month net profit, from 5 of 6 comparable companies. Prevest Denpro Ltd has the fastest profit growth at 17%, though growth off a small or recovering profit base overstates how much has actually changed.

### Which Medical Equipment company earns the highest return on capital?

Prevest Denpro Ltd leads on return on capital employed at 25.2%, across 6 of 6 companies. Read it beside the length of its reported history: a high return that repeats for years is evidence of a durable business, while a single high reading can be a small capital base or one good year.

### Which Medical Equipment stock is the cheapest?

On PEG — where a LOWER number is cheaper — Poly Medicure Ltd screens cheapest at 3.87×. Only 1 of 6 companies have earnings and growth steady enough for the ratio to mean anything, so this is not a sector-wide "cheapest stock" verdict. Cheap on a multiple is a reason to investigate, never a reason to buy on its own.

### Is the Medical Equipment sector beating the market?

Medical Equipment has underperformed NIFTY 500 by 19% over the last 52 weeks and 15.4% over 13 weeks, measured on an equal-weight index of its current members. Inside the sector, 3 of 6 covered companies are beating the market on their own. Sector strength does not transfer evenly to every stock in it.

### Which Medical Equipment stock has the strongest price momentum?

Tarsons Products Ltd has the strongest relative strength against NIFTY 500. Relative strength answers last, after growth, quality and valuation: price can move well before the fundamentals confirm it, and sometimes without them confirming at all.

### Which Medical Equipment company scores highest for research priority?

Prevest Denpro Ltd scores 71.3 out of 100 with 72.1% evidence confidence, from 23.4 points on growth and earnings, 20.8 on capital efficiency, 13.8 on valuation and 13.3 on relative strength. This ranks what deserves work next. It is not a buy recommendation, and management quality, catalysts and risk still need separate research.

### How many Medical Equipment companies does this comparison cover, and over what period?

It compares 6 listed companies over up to 20 reported quarters of fundamentals, ending Mar 2026, plus weekly price and relative-strength history. Membership is the full sector list — nothing is dropped for having thin data.

### What is the total market cap of the Medical Equipment sector?

The 6 Medical Equipment companies on this page carry ₹21,834 crore of combined market value. Poly Medicure Ltd is the largest at ₹17,251 crore, about 79% of the sector's total on its own. Market value moves with price, so this reading is dated 2026-08-05.

### What is the Medical Equipment sector's P/E ratio?

The median price-to-earnings ratio across the 6 Medical Equipment companies on this page is 52.7×, measured on the 6 that report a comparable figure. A sector-level history for this multiple is not held here, so this is a cross-section of today, not a comparison with the sector’s own past. Figures are as of 2026-08-05.

### How is the Medical Equipment sector performing?

3 of the 6 covered Medical Equipment companies are beating NIFTY 500 on Mansfield relative strength. The sector itself is 19% behind NIFTY 500 over 52 weeks on an equal-weight index of its current members. Readings are as of 2026-08-05.

### Why are some values on this page blank?

A blank means that company did not report a comparable figure for that period, so nothing is shown. Missing observations are never interpolated, carried forward, or replaced with a similar-looking accounting line, and a company with missing evidence has its research score pulled toward neutral rather than being scored as bad.

### Is this investment advice?

No. Every figure here is a deterministic calculation from reported company filings and market data, published for research. It contains no recommendation to buy or sell any security, does not account for your circumstances, and is not a substitute for advice from a licensed adviser.